The Group's principal activity is to discover, develop and market low molecular drugs for human health care. The Group's products include Tracleer for the treatment of pulmonary arterial hypertension and Zavesca for the treatment of Type I Gaucher's disease. The Group's operations are located in Switzerland, United States, Europe and Other Countries.
Alacra Alerts:
Receive alerts on the latest reports on Actelion Ltd.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
